Doctors Note Logo

Published on: 8/18/2026

Important Treatment Guide: How to Manage Asfotase Alfa Injections with Your Doctor

Managing asfotase alfa (Strensiq) injections with your doctor depends on several factors, and the important details are below. This enzyme replacement therapy for hypophosphatasia is given as a subcutaneous injection several times per week, with the dose calculated by body weight and re-adjusted by your clinician as your weight changes over time. Safe use includes correct refrigerated storage, rotating injection sites, avoiding skin that is red, bruised, or hardened, and tracking reactions such as pain, swelling, or fat loss at the site. Your doctor should also arrange ongoing monitoring, including eye exams and kidney imaging for calcium deposits, plus prompt reporting of allergic symptoms, new bone pain, or missed doses.

If you are noticing new symptoms, side effects, or changes you cannot explain, a free, instant, online symptom check can help you organize what you are experiencing and understand which concerns deserve urgent attention, so your next conversation with your care team is faster, clearer, and more productive.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Important Treatment Guide: How to Manage Asfotase Alfa Injections with Your Doctor

Asfotase alfa (brand name Strensiq) is an enzyme replacement therapy prescribed for hypophosphatasia, a rare inherited disorder affecting bone development. Regular injections help build stronger bones, improve muscle strength and enhance overall quality of life. Working closely with your healthcare team ensures you get the most benefit with the fewest complications.


Understanding Asfotase Alfa (Strensiq)

  • What it is: A laboratory-made form of alkaline phosphatase, the enzyme missing in hypophosphatasia.
  • How it works: Replaces the deficient enzyme, promoting healthy bone mineralization and reducing pain.
  • Who receives it: Infants, children and adults with confirmed hypophosphatasia.

Before starting therapy, your doctor will review medical history, perform physical exams and order baseline labs. Keep an up-to-date list of medications, supplements and allergies to share at every visit.


Choosing and Rotating Injection Sites

Picking the right injection spot and rotating locations helps reduce discomfort, bruising and the risk of tissue changes under the skin. Strensiq injection sites commonly include:

  • Thigh (anterolateral)
  • Abdomen (around the belly, avoiding 2 inches around the navel)
  • Upper arms (outer aspect)
  • Buttocks (upper outer quadrant)

Safe rotation prevents repeated trauma to the same area. For example, if you inject in the right thigh today, try the left thigh or abdomen on your next dose. Keep a simple chart or mobile app log to track sites and dates.


Preparing for Injection

Proper preparation ensures accurate dosing and lowers infection risk:

  1. Storage

    • Store refrigerated (2–8 °C).
    • Do not freeze.
    • Protect from light—keep the vial in its carton until use.
  2. Gather supplies

    • Prescribed dose of Strensiq (vial or prefilled syringe).
    • Alcohol swabs, sterile syringes and needles (as directed).
    • Sharps disposal container.
    • Gauze or cotton ball and adhesive bandage.
  3. Reconstitution (if needed)

    • Follow instructions from your pharmacy and doctor.
    • Use only sterile water provided or recommended diluent.
    • Gently swirl to mix—avoid shaking, which can damage the enzyme.
  4. Hand hygiene

    • Wash hands thoroughly with soap and warm water.
    • Dry hands with a clean towel or air dryer.

Administering the Injection Safely

  1. Clean the site

    • Wipe with an alcohol swab in a circular motion, from center outward.
    • Let the skin air-dry.
  2. Draw up the dose

    • If using a vial: insert needle, withdraw air to match dose, then invert and fill syringe.
    • Remove air bubbles by tapping syringe and pushing the plunger slightly.
  3. Inject

    • Pinch a fold of skin (subcutaneous technique).
    • Insert needle at a 45°–90° angle, based on your provider’s recommendation.
    • Inject medicine slowly and steadily.
  4. Withdraw and apply pressure

    • Remove needle and press lightly with gauze.
    • Do not rub the area—this can increase bruising.
  5. Dispose safely

    • Place used needles and syringes in an approved sharps container.
    • Seal the container when three-quarters full, per local guidelines.

Strensiq Injection Side Effects and How to Manage Them

Mild side effects are common and often improve with time. Discuss any ongoing or severe symptoms with your doctor.

Common Local Reactions

  • Redness, swelling or pain at the injection site
  • Bruising or itching
  • Small hard lump under the skin

Management tips:

  • Apply a cool compress for 10–15 minutes
  • Rotate injection sites
  • Use over-the-counter pain relief (ibuprofen or acetaminophen), if approved by your doctor

Systemic Side Effects

  • Headache
  • Fatigue or weakness
  • Muscle or joint pain

Management tips:

  • Stay well-hydrated
  • Rest and pace activities
  • Keep a symptom diary to share at follow-up visits

Less Common but Serious Effects

  • Allergic reactions (rash, itching beyond the injection site, difficulty breathing)
  • Rapid breathing or chest tightness
  • Swelling of face, lips or throat

If you notice these, seek immediate medical attention or call emergency services. Always carry a list of your medications and your treating physician’s contact information.


Working Closely with Your Doctor

Regular communication helps tailor treatment, monitor progress and catch issues early.

  • Dose adjustments
    • Based on weight changes, growth in children or lab results.
  • Laboratory monitoring
    • Alkaline phosphatase levels, calcium and vitamin D status, kidney function.
  • Imaging and functional tests
    • Periodic X-rays or bone density scans to assess bone health.
  • Symptom review
    • Pain, mobility, dental health and motor milestones (in infants/children).

Schedule follow-up visits as recommended—often every 2–4 weeks at first, then every 3–6 months once stable.


Tracking Progress and Symptoms

Keeping a consistent record empowers both you and your doctor:

  • Date, time and site of each injection
  • Any side effects and their duration
  • Changes in pain levels or mobility
  • New symptoms (fever, unusual fatigue, rash)

You might also consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide when to seek care or adjust your treatment plan.


Tips for a Smooth Treatment Experience

  • Choose a calm, well-lit space for injections.
  • Enlist a family member or caregiver, if you feel anxious or have mobility challenges.
  • Keep all supplies organized in a dedicated box or tray.
  • Reward yourself or your child after successful injections—positive reinforcement matters.
  • Review injection techniques periodically with your healthcare team.

When to Seek Immediate Medical Attention

Call emergency services or go to the nearest emergency department if you experience:

  • Signs of a severe allergic reaction (difficulty breathing, swelling of throat)
  • High fever (above 38.5 °C / 101.3 °F) not resolving with acetaminophen or ibuprofen
  • Sudden chest pain, shortness of breath or rapid heartbeat
  • Severe, persistent vomiting or diarrhea leading to dehydration

For any other concerns, contact your physician’s office promptly.


Conclusion and Next Steps

Asfotase alfa (Strensiq) injections can transform quality of life for people with hypophosphatasia when managed carefully. Partnering with your doctor on injection sites, monitoring for Strensiq injection side effects and keeping thorough records will help you stay on track.

Always speak to a doctor about any new, worsening or life-threatening symptoms. If you’re ever unsure whether a symptom warrants medical attention, use the free, online symptom check, using the doctor approved Ubie Symptom Checker or contact your healthcare provider right away. Your active involvement and timely communication are vital for safe, effective treatment.

(References)

  • * Orimo H. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa. Ther Clin Risk Manag. 2016;12:777-86. doi: 10.2147/TCRM.S87956. Epub 2016 May 17. PMID: 27274262; PMCID: PMC4876073.

  • * Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019 Feb;7(2):93-105. doi: 10.1016/S2213-8587(18)30307-3. Epub 2018 Dec 14. PMID: 30558909.

  • * Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866.

  • * Simon S, Resch H. Treatment of hypophosphatasia. Wien Med Wochenschr. 2020 Apr;170(5-6):112-115. doi: 10.1007/s10354-020-00736-3. Epub 2020 Feb 18. PMID: 32072352.

  • * Schroth RJ, Long C, Lee VHK, Alai-Towfigh H, Rockman-Greenberg C. Dental outcomes for children receiving asfotase alfa for hypophosphatasia. Bone. 2021 Nov;152:116089. doi: 10.1016/j.bone.2021.116089. Epub 2021 Jun 25. PMID: 34175501.

  • * Alsarraf F, Ali DS, Almonaei K, Al-Alwani H, Khan AA, Brandi ML. Hypophosphatasia: presentation and response to asfotase alfa. Osteoporos Int. 2024 Apr;35(4):717-725. doi: 10.1007/s00198-023-06943-z. Epub 2023 Nov 23. PMID: 37993691.

  • * Dahir KM, Shannon A, Dunn D, Voegtli W, Dong Q, Hasan J, Pradhan R, Pelto R, Pan WJ. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39(10):1412-1423. doi: 10.1093/jbmr/zjae128. PMID: 39135540; PMCID: PMC11425692.

  • * Padidela R, Bishop N, Arundel P, Fang S, Zygouras A, Mughal MZ, Shaw N, Saraff V. Mobility and Quality of Life in Children with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement. Adv Ther. 2025 Jul;42(7):3528-3546. doi: 10.1007/s12325-025-03225-4. Epub 2025 May 29. PMID: 40439960; PMCID: PMC12182503.

  • * Narisawa S, Amadeu de Oliveira F, Tokuhara CK, Lira Dos Santos EJ, Fonfria E, Batson J, Cheng Z, Houston A, Foster BL, Millán JL. ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia. J Bone Miner Res. 2026 Mar 2;41(3):310-323. doi: 10.1093/jbmr/zjaf136. PMID: 41051346; PMCID: PMC13017400.

  • * Carrillo MA, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine P, Yan M, Lee S, Kim NJ, Rodriguez R, Bishop P, Sanchez R, Orpilla J, Le Verche V, Xu S, Chen ISY, Kitchen S, Breton L, Bartlett JS, Do MH, Zhen A. Lentivirus-based HPSC therapy provides effective and long-term treatment in hypophosphatasia mouse model. Mol Ther. 2026 Jul 1;34(7):4200-4211. doi: 10.1016/j.ymthe.2026.03.008. Epub 2026 Mar 10. PMID: 41814653; PMCID: PMC13330071.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.